Palisade Bio, Inc.

Contributing Author

Recent Articles by Palisade Bio, Inc.

Apr-16	Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 PALI GlobeNewswire
Apr-08	Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference PALI GlobeNewswire
Mar-30	Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease PALI -11.00% GlobeNewswire
Mar-02	Palisade Bio Announces Participation in Two Upcoming Investor Conferences PALI GlobeNewswire
Feb-23	Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 PALI GlobeNewswire
Feb-17	Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board PALI GlobeNewswire
Feb-09	Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium PALI GlobeNewswire
Feb-05	Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference PALI -5.06% GlobeNewswire
Jan-29	Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board PALI GlobeNewswire
Jan-16	Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences PALI -5.14% GlobeNewswire
Jan-07	Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 PALI +5.21% GlobeNewswire
Dec-30	Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 PALI GlobeNewswire
Dec-02	Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development PALI GlobeNewswire
Nov-25	Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference PALI -5.70% GlobeNewswire
Oct-28	Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations PALI +11.45% GlobeNewswire
Oct-20	Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD) PALI +6.90% GlobeNewswire
Oct-13	Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 PALI -7.50% GlobeNewswire
Oct-09	Palisade Bio Announces Cancellation of Special Meeting of Stockholders PALI GlobeNewswire
Oct-02	Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option PALI +29.77% PALI -5.88% GlobeNewswire
Oct-01	Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock PALI +52.38% GlobeNewswire
Sep-26	Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum PALI +16.20% GlobeNewswire
Sep-18	Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum PALI GlobeNewswire
Sep-17	Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data PALI GlobeNewswire
Sep-05	Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD) PALI GlobeNewswire
Aug-25	Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108 PALI -8.46% GlobeNewswire
Aug-07	Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108 PALI -12.16% GlobeNewswire
Jul-31	Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China PALI GlobeNewswire
Jul-23	Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million PALI -9.02% GlobeNewswire
Jul-22	Palisade Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference PALI -9.20% GlobeNewswire
Jul-09	Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors PALI +5.41% GlobeNewswire
May-27	Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis PALI GlobeNewswire
May-06	Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases PALI +6.07% GlobeNewswire
May-01	Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit PALI GlobeNewswire

Palisade Bio, Inc.

Recent Articles by Palisade Bio, Inc.

Upgrade your Finviz experience